Investors
OMX Stockholm
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Upcoming events
Annual Report 2024
Interim Report for January-March 2025
Annual General Meeting 2025
Press releases
Our latest press releases
Regulatory press release
06/02/2025
23/01/2025
07/01/2025
Regulatory press release
17/12/2024
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Upcoming
Key progress and look ahead
| Progress to date | Next anticipated milestone | |
|---|---|---|
| AUTOIMMUNE | TRIAL COMPLETED: 15-MedIdeS-09 (GBS) Ph 2 trial and data contextualization ENROLLMENT COMPLETED: GOOD-IDES-2 Ph 3 (anti-GBM) trial COMPLETED: NICE-01 Ph 1 study of HNSA-5487 with data on exploratory endpoints and clinical development path selected | 15-MedIdeS-09 Ph 2 (GBS) Publication in peer-reviewed journal Preparation of Ph 3 trial in GBS GOOD-IDES-2 Ph 3 (anti-GBM) data readout in 2025 HNSA-5487: Alignment with regulatory authorities on clinical development pathway in neuro-autoimmune diseases |
| GENE THERAPY | STUDY INITIATED: SRP 9001-104 Ph 1 study (DMD) - Sarepta STUDY INITIATED: GNT-018-IDES Ph 2 study (Crigler-Najjar) - Genethon AskBio (Pompe) preclinical | SRP 9001-104 Ph 1 study (DMD) completion of enrollment GNT-018-IDES study (Crigler-Najjar) completion of enrollment |
| TRANSPLANTATION | FULL RANDOMIZATION: ConfIdeS Ph 3 trial DATA PUBLISHED: 15-HMedIdeS-14 data publication in peer reviewed journal | ConfIdeS Ph 3 12 month follow up and BLA submission in 2H 2025 Post Approval Efficacy Study (PAES) readout |
